- Tearin’ up my tweet: ‘N Sync’s Lance Bass promotes wrong Obamacare website
- Oil rig worker says he saw missing plane go down: report
- Pentagon: U.S. F-16 fighter jets to train with Poland near Ukraine
- Jerry Sandusky’s wife: Victims manipulated over money
- Ben Carson: America’s now ‘very much like Nazi Germany’
- Heroin found on N.J. toddler at day care
- Pistorius trial: Police conduct faces scrutiny
- Gaza militants fire large rocket barrage at Israel
- CBO chief: Projected job loss numbers from minimum wage hike are fluid
- Rep. Rangel: ‘No question’ Harlem explosion is result of gas leak, not terrorism
Myriad Genetics Inc.
Latest Myriad Genetics Inc. Items
Nothing is more personal than the blueprint of life itself, encoded in the DNA that comes with the gift of birth. Advances in medical technology have given scientists the power to read what's written in those genes, and there's the problem.
The Supreme Court says companies cannot patent human genes, a decision that could profoundly affect the medical and biotechnology industries.
The Supreme Court on Thursday ruled that human genes cannot be patented by companies that extract them from nature without actually creating anything.
The Supreme Court on Thursday ruled unanimously that human genes are "a product of nature" and companies cannot obtain patents on them — a major shift in patent policy that could open the door to broader medical research on certain cancers and other diseases.
The Supreme Court seemed worried Monday about the idea of companies patenting genes that can be found inside the human body, as it heard arguments in a case that could profoundly reshape U.S. medical research and the fight against diseases such as breast and ovarian cancer.
The Supreme Court on Monday threw out a lower court ruling allowing human genes to be patented, a topic of enormous interest to cancer researchers, patients and drug makers.